Du är här


Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics appoints a new Chief Medica...

STOCKHOLM, 15 March 2018. Karolinska Development's portfolio company Modus
Therapeutics, focused on sickle cell disease (SCD) and malaria, announces
that Dr. John Öhd has been appointed to a position as Chief Medical Officer
Dr. Öhd has up to today been working at Medivir AB as their CMO and a member
of the company`s Executive Management team. Before his current position, John
was Medivir's Director of Clinical R&D. Prior to joining Medivir, John was
Senior director of Experimental Medicine at Shire based in Nyon, Switzerland.
Between 2007 and 2012, Dr. Öhd held several positions of increasing
responsibility at AstraZeneca in Södertälje, Sweden.
"We are delighted that we have been able to attract Dr. Öhd as our new CMO.
John not only has extensive clinical development experience, but he brings to
Modus important prior experience working on SCD at Shire. I am confident that
he will make important contributions to Modus as we progress the clinical
development of sevuparin for SCD", states Ellen K. Donnelly, CEO of Modus
For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB

Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying breakthrough medical
innovations in the Nordic region that are developed by entrepreneurs and
leadership teams. The Company invests in the creation and growth of companies
that advance these assets into commercial products that are designed to make
a difference to patients' lives while providing an attractive return on
investment to shareholders.

Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes
in the Nordic region. The Company aims to build companies around scientists
who are leaders in their fields, supported by experienced management teams
and advisers, and co-funded by specialist international investors, to provide
the greatest chance of success.

Karolinska Development has established a portfolio of ten companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with
a proven track record as company builders and with access to a strong global

For more information, please visitwww.karolinskadevelopment.com
About sevuparin

Sevuparin is an innovative, proprietary polysaccharide drug, which has the
potential to restore blood flow and prevent further microvascular
obstructions, caused by abnormal blood cells in SCD patients. With its
anti-adhesive properties, sevuparin could thereby offer treatment of the
underlying cause of vaso-occlusive crisis (VOC) in SCD patients, with earlier
pain relief, shorter hospital stays, reduced need of opioids and improved
quality of life. Modus is currently enrolling patients in a Phase II study
with the aim to complete the study in late 2018.
About sickle cell disease

Sickle cell disease (SCD) is a painful, inherited blood disorder affecting
millions of people around the globe and the most common inherited blood
disorder in the U.S. affecting between 90,000-100,000 subjects, with medical
care costs amounting to more than $1 billion. In Europe it is estimated that
there are 35,000-40,000 SCD patients, and this number is higher in the Middle
East and North Africa regions, with over 850,000 SCD patients. There is
currently no pharmaceutical product available that targets the underlying
cause of VOC:s that affect SCD patients.

Karolinska Development Modus new CMO march 2018

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.